A research team has identified novel molecular mechanisms underlying several chronic inflammatory diseases, according to a study published in Nature Medicine.
The researchers analyzed immune cell behavior in patients with rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
In laboratory tests, compounds that inhibit the TXNIP pathway reduced inflammation markers by 60-75% without affecting normal immune responses.